Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.58 |
| ▸ | TDP2 | O95551 | 3/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.50 |
| ▸ | CDK1 | P06493 | 4/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.50 |
| ▸ | AHR | P35869 | 2/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.46 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324288 | 0.84 | CCNB2 (0.49) | PGRTDP2CCNB2CDK1CCNB1 | |
| SCHEMBL6328529 | 0.83 | BRD4 (0.54) | PGRTDP2CCNB2CDK1CCNB1 | |
| SCHEMBL6319302 | 0.83 | CREBBP (0.59) | PGRTDP2CCNB2CDK1CCNB1 | |
| SCHEMBL5843496 | 0.82 | JAK2 (0.51) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL6321593 | 0.82 | TDP2 (0.52) | TDP2CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL155873 | 0.82 | GSK3B (0.50) | PGRTDP2CCNB2CDK1CCNB1 | |
| SCHEMBL10712645 | 0.82 | TDP2 (0.52) | TDP2CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL16090379 | 0.80 | BRD4 (0.52) | PGRTDP2CCNB2CDK1CCNB1 | |
| SCHEMBL6320773 | 0.78 | TDP2 (0.55) | TDP2CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL6320969 | 0.78 | GSK3B (0.53) | TDP2CCNB2CDK1CCNB1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
| US-4670566-A | ANTIIFLAMMATORY AGENTS, ANTICOAGULANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-06-02 | — | — | US | disclosed |
| EP-0089426-B1 | 2-AMINO-6-BIPHENYLACETIC ACIDS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-06-11 | — | — | EP | disclosed |
| US-4440785-A | Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation | A. H. ROBINS COMPANY, INC. (US) | 1984-04-03 | — | — | US | disclosed |
| EP-0089426-A1 | 2-Amino-6-biphenylacetic acids | A.H. ROBINS COMPANY, INCORPORATED (US) | 1983-09-28 | — | — | EP | disclosed |
| US-4333951-A | MUSCLE RELAXANTS, ANTIINFLAMMATORY AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1982-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | PGR 1080/4885TDP2 1952/4885CCNB2 694/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | PGR 1080/4885TDP2 1952/4885CCNB2 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.